Pediatric Cardiology

, Volume 28, Issue 1, pp 27–33 | Cite as

Effect of Microalbuminuria Lowering on Regression of Left Ventricular Hypertrophy in Children and Adolescents with Essential Hypertension



Microalbuminuria (MA) is associated with increased cardiovascular risk in adult hypertensive patients, but no study has specifically examined the effects of MA lowering on regression of left ventricular hypertrophy (LVH) among pediatric patients with hypertension. Fifty-five patients with essential hypertension, 11–19 years old, were prospectively studied. All patients received concomitant therapy of hydrochlorothiazide and angiotensin-converting enzyme inhibitor. Five patients also required angiotensin receptor blocker to achieve the blood pressure goal. Baseline and 12-month follow-up measures of left ventricular mass index (LVMI), determined by echocardiography and urine microalbumin/creatinine ratio (MA/Cr), were collected. MA was defined as MA/Cr >30 μg/mg. LVH was defined as LVMI >38.6 g/m2.7. The primary end points were reductions in MA and LVMI of 25% or more. Weight (r = 0.83), body surface area (r = 0.85), body mass index (BMI) (r = 0.86), systolic blood pressure (SBP) (r = 0.57), diastolic blood pressure (DBF) (r = 0.49), mean arterial pressure (r = 0.53) and MA (r= 0.87) were all univariate correlates of LVMI. In a multiple regression analysis, MA, BMI and SBP were significant correlates of LVMI. MA alone explained 76% of the variance of LVMI, whereas BMI and SBP explained only 1.6 and 0.4% of the variance, respectively. MA was the most significant correlate of follow-up LVMI after BMI and SBP were included in the overall multiple regression models. Thus, MA is a strong predictor of LVH in hypertensive children and adolescents. MA lowering halts the progression of LVH or induces its regression.


Microalbuminuria Hypertension Left ventricular hypertrophy 


  1. 1.
    Agrawal B, Berger A, Wolf K, Luft FC (1996) Microalbuminuria screening by reagent strip predicts cardiovascular risk in hypertension. J Hypertens 14:223–228PubMedCrossRefGoogle Scholar
  2. 2.
    Assadi F (2002) Quantitation of microalbuminuria using random urine samples. Pediatr Nephrol 17:107–110PubMedCrossRefGoogle Scholar
  3. 3.
    Asselbergs FW, Diercks FH, Hillege HL, et al. (2004) Effects of fosinopril and pravastatin on cardiovascular events in microalbuminuric subjects: results of the PREVEND IT. Circulation 10:2809–2816CrossRefGoogle Scholar
  4. 4.
    Brenner BM, Cooper M, de Zeeuw D, et al. RENAAL Study Investigators (2001) Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345:861–869PubMedCrossRefGoogle Scholar
  5. 5.
    Briars GL, Bailey BG (1994) Surface area estimation: pocket calculator versus nomogram. Arch Dis Child 70:246–247PubMedCrossRefGoogle Scholar
  6. 6.
    Daniels SR, Kimball TR, Morrison JA, Khoury P, Meyer RA (1995) Indexing left ventricular mass to account for differences in body size in children and adolescents without cardiac disease. Am J Cardiol 76:699–701PubMedCrossRefGoogle Scholar
  7. 7.
    Dell’Omo G, Penno G, Giorgi D, et al. (2002) Association between high-normal albuminuria and risk factors for cardiovascular and renal disease in essential hypertensive men. Am J Kidney Dis 40:1–8PubMedCrossRefGoogle Scholar
  8. 8.
    De Simone G, Daniels SR, Devereux RB, et al. (1992) Left ventricular mass and body size in normotensive children and adults: assessment of allometric relations and impact of overweight. J Am Coll Cardiol 20:1251–1260PubMedCrossRefGoogle Scholar
  9. 9.
    De Simone G, Devereux RB, Daniels SR, et al. (1995) Effect of growth on variability of left ventricular mass: assessment of allometric signals in adults and children and their capacity to predict cardiovascular risk. J Am Coll Cardiol 25:1056–1062PubMedCrossRefGoogle Scholar
  10. 10.
    Devereux RB, Alonso DR, Lutas EM, et al. (1986) Echocardiograph assessment of left ventricular hypertrophy: comparison to necroscopy findings. Am J Cardiol 75:450–458CrossRefGoogle Scholar
  11. 11.
    De Zeeuw (2004) Albuminuria, not only a cardiovascular/renal risk marker, but also a target for treatment? Kidney Int 66(Suppl 92):S2–S6Google Scholar
  12. 12.
    Festa A, D’Agostino O, Howard G, et al. (2000) Inflammation and microalbuminuria in nondiabetic and type 2 diabetic subjects; the Insulin Resistance Atherosclerosis Study. Kidney Int 58:1703–1710PubMedCrossRefGoogle Scholar
  13. 13.
    Gansevoort RT, de Zeeuw D, de Jong PE (1994) Is the antiproteinuric effect of ACE inhibition mediated by interference in the rennin–angiotensin system? Kidney Int 45:861–867PubMedGoogle Scholar
  14. 14.
    Grandi AM, Santillo R, Bertolini A, et al. (2001) Microalbuminuria as a marker of preclinical diastolic dysfunction in never treated essential hypertensives. Am J Hypertens 14:644–648PubMedCrossRefGoogle Scholar
  15. 15.
    Herbert LA, Wilmer WA, Falkenhain ME, et al. (2001) Renoprotecion: one or many therapies? Kidney Int 59:1211–1226CrossRefGoogle Scholar
  16. 16.
    Hillege HL, Fidler V, Diercks GF, et al. PREVEND Study Group (2002) Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation 106:1777–1782PubMedCrossRefGoogle Scholar
  17. 17.
    Ibsen H, Olsen MH, Wachtell K, et al. (2005) Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients: Losartan Intervention for Endpoint Reduction in Hypertension Study. Hypertension 45:198–202PubMedCrossRefGoogle Scholar
  18. 18.
    Jafar TH, Stark PC, Schmid CH, et al. AIPRD Study Group (2003) Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin converting enzyme inhibition. Ann Int Med 139:244–255PubMedGoogle Scholar
  19. 19.
    Jager A, Kostense PJ, Ruhe HG, et al. (1999) Microalbuminuria and peripheral arterial disease are independent predictors of cardiovascular and all-cause mortality, especially among hypertensive subjects; five-year follow-up of the Hoorn Study. Arterioscler Thromb Vase Biol 19:617–624Google Scholar
  20. 20.
    Jensen JS, Feldt-Rasmussen BO, Strandgaard S, Schroll M, Borch-Johnson K (2000) Arterial hypertension, microalbuminuria, and risk of ischemic heart disease. Hypertension 35:898–903PubMedGoogle Scholar
  21. 21.
    Julius S, Nesbitt SD, Egan BM, et al. (2006) Feasibility of treating prehypertension with an angiotensin-receptor blocker. N Engl J Med (in press, Epub ahead of print)Google Scholar
  22. 22.
    Knight EL, Kramer HM, Curhan GC (2003) High-normal blood pressure and microalbuminuria. Am J Kidney Dis 41:588–595PubMedCrossRefGoogle Scholar
  23. 23.
    Kotchen TA, Piering AW, et al. (2000) Glomerular filtration in hypertensive African Americans. Hypertension 35:822–826PubMedGoogle Scholar
  24. 24.
    Mattman A, Eintracht S, Mock T, et al. (2006) Estimating pediatric glomerular filtration rates in the era of chronic kidney disease staging. J Am Soc Nephrol 17:485–496CrossRefGoogle Scholar
  25. 25.
    Nathan DM, Rosenbaum C, Protasowski VD (1987) Single-voided samples can be used to estimate quantitative proteinuria. Diabetes Care 10:414–418PubMedGoogle Scholar
  26. 26.
    National High Blood Pressure Education Program Working Group on High Blood Pressure in Children, Adolescents (2004). The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. Pediatrics 114:555–576CrossRefGoogle Scholar
  27. 27.
    Ogden CL, Kuczmarski RJ, Flegal KM, et al. (2002) Centers for Disease Control and Prevention 2000 growth charts for the United States: improvements to the 1977 National Center for Health Statistics version. Pediatrics 109:45–60PubMedCrossRefGoogle Scholar
  28. 28.
    Pedrinelli R, Dell’Omo G, Di Bello V, Pontremoli R, Mariani M (2002) Microalbuminuria, an integrated marker of cardiovascular risk in essential hypertension. J Hum Hypertens 16:79–89PubMedCrossRefGoogle Scholar
  29. 29.
    Pendrinelli R, Giampietro O, Carmassi F, et al. (1994) Microalbuminuria and endothelial dysfunction in essential hypertension. Lancet 344:14–18CrossRefGoogle Scholar
  30. 30.
    Pontremoli R, Ravera M, Viazzi F, et al. (2000) Genetic polymorphism of the rennin–angiotensin system and organ damage in essential hypertension. Kidney 57:561–569CrossRefGoogle Scholar
  31. 31.
    Reddan D, Owen W (2001) IgA nephropathy and inhibitors of the renin–angiotensin system: is reduction in proteinuria adequate proof of efficacy? Am J Kidney Dis 28:182–185Google Scholar
  32. 32.
    Rodicio J, Campo C, Ruilope L (1998) Microalbuminuria in essential hypertension. Kidney Int 54:551–554CrossRefGoogle Scholar
  33. 33.
    Schwartz GJ, Haycock GB, Edelmann CM Jr, Spitzer A (1976) Predicting glomerular filtration rate in children derived from body length and plasma creatinine. Pediatrics 106:522–526Google Scholar
  34. 34.
    The ACE Inhibitors in Diabetic Nephropathy Trialist Group (2001) Should all patients with type 1 diabetes mellitus and microalbuminuria receive angiotensin-converting enzyme inhibitors? Ann Intern Med 34:370–379Google Scholar
  35. 35.
    Vasan RS, Larson MG, Leio EP, et al. (2001) Impact of high-normal blood pressure on the risk of cardiovascular disease. N Engl Med 45:1291–1297CrossRefGoogle Scholar
  36. 36.
    Viberti G, Wheeldon NM (2002) Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus. A blood pressure independent effect. Circulation 106:672–678PubMedCrossRefGoogle Scholar
  37. 37.
    Virdis A, Schiffrin EL (2003) Vascular inflammation: a role in vascular disease in hypertension? Curr Opin Nephrol Hygertens 12:181–187CrossRefGoogle Scholar
  38. 38.
    Wachtell K, Palmieri V, Olson MH, et al. (2002) Urine albumin/creatinine ratio and electrocardiographic left ventricular structure and function in hypertensive patients with electrocardiographic left ventricular hypertrophy: The LIFE study. Losartan Intervention for Endpoint Reduction. Am Heart J 143:319–326PubMedCrossRefGoogle Scholar
  39. 39.
    Wang TJ, Evans JC, Meigs JB, et al. (2005) Low-grade albuminuria and risks of hypertension and high blood pressure. Circulation 111:l370–1376CrossRefGoogle Scholar
  40. 40.
    Wolf G, Ritz E (2005) Combination therapy with ACE inhibitors and angiotensin-receptor blockers to halt progression of chronic renal disease: pathophysiology and indications. Kidney Int 67:799–812PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, Inc. 2007

Authors and Affiliations

  1. 1.Rush Children’s HospitalChicagoUSA
  2. 2.Department of Pediatrics, Section of NephrologyRush University Medical CenterChicagoUSA

Personalised recommendations